PReS-FINAL-2138: Abatacept (orencia) in treatment of different types of juvenile idiopathic arthritis

Methods 30 children with JIA were treated with ABA. 23 (77%) pts had polyarticular course of JIA and 7 (23%) systemic JIA. 11 children were diagnosed with acute uveitis (totally 14 affected eyes). 28 (93%) of pts were female. All patients had high degree (III) of disease activity. Mean disease duration was 6,1 ± 3,2 yr. 29 patients previously had an inadequate response to 2 or more non-biological, one child with heavy course of systemic JIA was treated with infliximab during 1 year before starting ABA. Treatment effectiveness was assessed according to the ACR Pediatric criteria: ACR pedi 30, ACR pedi 50, acrpedi 70, and ACR pedi 90 after 6 and 12 months of abatacept therapy. All patients received ABA in dose 10 mg/kg at day 1, week 2 and 4 and every 4 weeks thereafter. Results In the group of pts with systemic JIA after 6 months of ABA treatment 6 of 7 patients (86%) achieved ACR Pedi 30 response, 5 (71%) ACR Pedi 50, and 3 (43%) ACR Pedi 70. 12 months data was available for 5 patients (others are still on treatment but less than 12 moths). Four of five pts (80%) achieved ACR pedi-30, 3(60%) ACR Pedi 50 response, 2 (40%) ACR pedi 70, and 1 (20%) ACR pedi 90. In the group of pts with poliarticular course of JIA treatment effectiveness was assessed in 22 pts. One girl had experienced an infusion-related reaction (potentially associated with hypersensitivity) after 3 infusion and ABA treatment was stopped. After 6 months 20 of 22 pts (91%) achieved ACR pedi 30 response, 17 (77%) ACR pedi-50, 9 (41%) ACR pedi-70, 2 (9%) ACR pedi 90. 14 of 22 patients with polyarticular JIA have completed 12 months of ABA treatment. 12 of them (86%) achieved ACR pedi 30 response, 11 (78%) ACR pedi 50, 8 (57%) ACR pedi 70 and 2 (14%) ACR pedi 90. Abatacept also showed efficacy in treatment of JIA associated uveitis. After 6 months of treatment the count of affected eyes was significantly reduced. In 72% of patients complete remission of uveitis was achieved. Adverse events were observed in 2 patients (6,7%): 1 case of infusion related reaction, 1 pts experienced common Herpes simplex infection (ABA treatment was stopped after 12 months).